Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BF-derm 1

Latest Information Update: 20 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biofrontera AG
  • Class Skin disorder therapies
  • Mechanism of Action Histidine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Urticaria

Highest Development Phases

  • Phase II Urticaria

Most Recent Events

  • 20 Aug 2015 BF-derm1 is still in phase-II development for Urticaria in Europe
  • 27 Jul 2009 BF-derm1 is available for licensing (http://www.biofrontera.com)
  • 27 Jul 2009 Efficacy and adverse events data from a phase II trial in Urticaria released by Biofrontera
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top